118 related articles for article (PubMed ID: 22510032)
1. Novel molecular targets for the therapy of urothelial carcinoma.
Jana BR; Galsky MD; Hahn NM; Milowsky MI; Sonpavde G
Expert Opin Ther Targets; 2012 May; 16(5):499-513. PubMed ID: 22510032
[TBL] [Abstract][Full Text] [Related]
2. Novel Molecular Targets for the Therapy of Urothelial Cancer.
Jana BR; Zhou Y
Anticancer Res; 2015 Sep; 35(9):4557-67. PubMed ID: 26254343
[TBL] [Abstract][Full Text] [Related]
3. Emerging drugs for urothelial carcinoma.
Gartrell BA; Sonpavde G
Expert Opin Emerg Drugs; 2013 Dec; 18(4):477-94. PubMed ID: 24195728
[TBL] [Abstract][Full Text] [Related]
4. Emerging drugs for urothelial (bladder) cancer.
Cumberbatch K; He T; Thorogood Z; Gartrell BA
Expert Opin Emerg Drugs; 2017 Jun; 22(2):149-164. PubMed ID: 28556678
[TBL] [Abstract][Full Text] [Related]
5. Novel molecular targets for urothelial carcinoma.
Faltas BM; Karir BS; Tagawa ST; Rosenberg JE
Expert Opin Ther Targets; 2015 Apr; 19(4):515-25. PubMed ID: 25633079
[TBL] [Abstract][Full Text] [Related]
6. Targeted agents in second-line bladder cancer therapy.
Gerullis H; Otto T; Ecke TH
Anticancer Drugs; 2012 Nov; 23(10):1003-15. PubMed ID: 22914698
[TBL] [Abstract][Full Text] [Related]
7. Molecular biology and targeted therapies for urothelial carcinoma.
Seront E; Machiels JP
Cancer Treat Rev; 2015 Apr; 41(4):341-53. PubMed ID: 25828962
[TBL] [Abstract][Full Text] [Related]
8. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.
Ortmann CA; Mazhar D
Future Oncol; 2013 Nov; 9(11):1637-51. PubMed ID: 24156324
[TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
Galsky MD; Seng S; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
Clin Genitourin Cancer; 2011 Sep; 9(1):27-30. PubMed ID: 21700509
[TBL] [Abstract][Full Text] [Related]
10. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium.
Sonpavde G; Sternberg CN; Rosenberg JE; Hahn NM; Galsky MD; Vogelzang NJ
Lancet Oncol; 2010 Sep; 11(9):861-70. PubMed ID: 20537950
[TBL] [Abstract][Full Text] [Related]
11. Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma.
Kurtoglu M; Davarpanah NN; Qin R; Powles T; Rosenberg JE; Apolo AB
Clin Genitourin Cancer; 2015 Oct; 13(5):410-20. PubMed ID: 25862322
[TBL] [Abstract][Full Text] [Related]
12. Novel agents for muscle-invasive and advanced urothelial cancer.
Sonpavde G; Ross R; Powles T; Sweeney CJ; Hahn N; Hutson TE; Galsky MD; Lerner SP; Sternberg CN
BJU Int; 2008 Apr; 101(8):937-43. PubMed ID: 18005203
[TBL] [Abstract][Full Text] [Related]
13. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
Siu LL; Banerjee D; Khurana RJ; Pan X; Pflueger R; Tannock IF; Moore MJ
Clin Cancer Res; 1998 Mar; 4(3):559-65. PubMed ID: 9533522
[TBL] [Abstract][Full Text] [Related]
14. Systemic chemotherapy for urothelial cancer.
Sonpavde G; Hutson TE; Berry WR
Clin Genitourin Cancer; 2006 Jun; 5(1):34-42. PubMed ID: 16859577
[TBL] [Abstract][Full Text] [Related]
15. Urothelial cancers: using biology to improve outcomes.
Pezaro C; Liew MS; Davis ID
Expert Rev Anticancer Ther; 2012 Jan; 12(1):87-98. PubMed ID: 22149435
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium.
Vaughn DJ
Cancer Treat Rev; 2008 Jun; 34(4):328-38. PubMed ID: 18262363
[TBL] [Abstract][Full Text] [Related]
17. Systemic treatments for metastatic urothelial carcinoma.
Lalani AA; Sonpavde GP
Expert Opin Pharmacother; 2019 Feb; 20(2):201-208. PubMed ID: 30412003
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy in advanced urothelial carcinoma.
Verdoorn BP; Kessler ER; Flaig TW
Oncology (Williston Park); 2013 Mar; 27(3):219-26. PubMed ID: 23687793
[TBL] [Abstract][Full Text] [Related]
19. Treatment of metastatic urothelial cancer: opportunities for drug discovery and development.
Sonpavde G; Sternberg CN
BJU Int; 2008 Nov; 102(9 Pt B):1354-60. PubMed ID: 19035904
[TBL] [Abstract][Full Text] [Related]
20. Systemic chemotherapy for advanced bladder cancer: update and controversies.
Garcia JA; Dreicer R
J Clin Oncol; 2006 Dec; 24(35):5545-51. PubMed ID: 17158540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]